Recent Stories
Keeping the Human in Medicine: Two AI CoLab Researchers on What Machines Can’t ReplaceSomeone Is Hacking the Freezers. Pay Attention.Thinking of Running in 2028? Start HereWhat the Lame Duck Session Has to Do With the Ultimate 21st-Century Power Tool: RobotsBlack October Wasn't an Attack Wave. It Was a Warning.Extreme Ownership Means Ultimate Achievement – NASA Culture Shift
← Back to the board
Hill

Two House Republicans on the China committee and an appropriations panel asked the FDA to bar Chinese trial data lacking a recent site audit, citing undisclosed deaths in Chinese gene-editing trials.

Why it’s here: A House Select Committee letter to FDA urging restrictions on China-generated clinical trial data in US drug applications is squarely a biotechnology policy item tied to China competition and FDA regulation.

Trace across the board

Item

Connected

21 links

About

  • China
  • John Moolenaar
  • Food and Drug Administration
  • House Select Committee on the CCP

Analytics cookies help us see how the site is used. They only run if you accept. Privacy Policy

Two House Republicans on the China committee and an appropriations panel asked the FDA to bar Chinese trial data lacking a recent site audit, citing undisclosed deaths in Chinese gene-editing trials. — The Wave